Work

A phase 1b dose-escalation study of TRC105 (endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC)

Year: 2016

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw373.32

Authors: T. Choueiri, M.D. Michaelson, E. Posadas, G. Sonpavde, D. McDermott, B. Seon, M. Jivani, R. Shazer, B. Adams, C. Theuer

Institutions: Dana-Farber Cancer Institute, Massachusetts General Hospital, Cedars-Sinai Medical Center, University of Alabama at Birmingham Hospital, Beth Israel Deaconess Medical Center, Roswell Park Comprehensive Cancer Center, Tracon Pharmaceuticals (United States)

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2587766890

FWCI: 0.794

Cites:

Cited by: 5

Related to: 10